Millennium Partners cash boosts liquidity at StemCells:
This article was originally published in Clinica
Millennium Partners has exercised an option to buy 457,750 shares of StemCells for a total of $2 million. In August 2000, the investment fund put $5 million into the Palo Alto, California-based company. StemCells said that this and other finance sources will allow it to speed up its internal R&D and in particular its neuronal stem cell programme.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.